Sun Pharmaceutical Industries has received regulatory clearance from the Drugs Controller General of India to manufacture and market a generic version of semaglutide injection for chronic weight management.
The approval marks another step in the company’s expansion in cardiometabolic therapies and comes ahead of the expiry of the semaglutide patent in India, after which the product will be introduced to the market.
Sun Pharma has been granted permission to produce and distribute a generic semaglutide injection indicated for weight management in adults, alongside dietary and lifestyle interventions.
The company plans to launch the product under the brand name Noveltreat once the existing semaglutide patent in India expires.
The approval follows a review of Phase III clinical trial data generated in India, supporting the product’s safety and efficacy. The medicine will be offered in multiple dose strengths and administered through a prefilled pen device designed to enable accurate self-dosing.
The company has highlighted obesity and diabetes as growing healthcare concerns in India. GLP-1 receptor agonist therapies such as semaglutide are increasingly being considered as part of broader treatment approaches for metabolic conditions when combined with appropriate medical supervision and lifestyle changes.
Sun Pharma has indicated that the introduction of a generic semaglutide option aims to widen access to this category of treatment following patent expiry.
In addition to the weight management indication, Sun Pharma received DCGI approval in December 2025 to manufacture and market semaglutide for adults with type 2 diabetes whose condition is not adequately controlled through diet and exercise alone. This formulation will be launched under a separate brand name after patent expiry.
These approvals reflect the company’s ongoing efforts to broaden its portfolio in therapies addressing metabolic disorders.
Sun Pharmaceutical Industries’ shares were trading around ₹1,636 at 2:15 PM, marginally higher than the previous close. The stock opened at ₹1,640 and moved between ₹1,648.90 and ₹1,625.40 during the day’s trade.
Read More: Bandhan Bank Shares in Focus After Mixed Q3FY26 Performance.
Sun Pharma’s DCGI approvals for generic semaglutide mark progress in its strategy to strengthen its presence in cardiometabolic care. The planned launches, aligned with patent expiries, may contribute to wider treatment access in India. Future developments will depend on execution timelines, market uptake and evolving regulatory conditions.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 23, 2026, 2:48 PM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
